Ref ID: 18720
Author:
V. Chrenkova, MD – physician1, P. Hubacek, MD, Ph.D. – Research Assistant 2, P. Sedlacek, MD, PhD – Professor 2, P. Keslova, MD – physician 2, E. Kabickova, MD, PhD – Research Assistant 2, E. Mejstrikova, MD, PhD – Research Assistant 2, V. Smelhaus,
Author address:
1Motol Univ. Hosp., Prague, Czech Republic, 2Charles Univ. 2nd Faculty of Med. and Motol Univ. Hosp., Prague, Czech Republic.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: Data on invasive fungal diseases (IFD) in the hemato-oncological pediatric patients are limited. We performed retrospective analysis of IFD incidence in our patients at risk. Methods: We analyzed patients treated in Department of Pediatric Hematology and Oncology, in Motol University Hospital from I/2002 to XII/2010 and stratified them into risk groups (high risk – HR x low risk – LR) according to the ECIL 4 guidelines. The detected IFD cases were analyzed by the use of EORTC/MSG criteria and the incidence of proven and probable IFD in HR and LR group was calculated using basic statistical methods. Results: There have been 621 patients treated by 447 HR and 296 LR treatment courses during the selected period. 36 cases of proven/probable IFD were detected (26 in HR episodes – 5.8 % and 10 in LR – 3.4 %): 15 aspergilloses, 13 candidiases, 7 mucormycoses and 1 hormographiella/coprinus, this represents 42 %, 36 %, 19 % and 3 % of IFD respectively. The incidence was 5.8 % in HR group (27 cases) and 3.4 % in LR group (10 cases). There was no significant difference in number of patients in the selected period. The incidence of IFD was 5.6 % in allogeneic transplant recipients and 5.3 % in AML, 5.9 % in ALL and 4.7 % in NHL. The incidence of mucormycosis was found significantly higher than aspergillosis in 2008-2010 (p=0.02, Fisher’s exact test). The mortality rate of IFD was 52.8 % (47% of aspergilloses, 46 % of candidiases and 71 % of mucormycoses). Conclusions: The high rate of mucormycosis of 18.9 % of IFD and significant increase of its incidence during last years could be related to the reconstruction works started in 2006 with the maximum of activity in 2008. The influence of azoles in prophylaxis and the use of more aggressive treatment courses are to be evaluated. Acknowledgements: The data were partially collected in coordination with Czech Leukemia Group for Life and FIND database. Supported by Institutional Science Support of University Hospital Motol 00064203
Abstract Number: T-344
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Felix Bongomin (UG)
2024
41
n/a
-
v
Khostelidi S1,2, Borzova Y2., Shadrivova O1, Desyatik E2., Karpishchenko S3 ., Charushin A.O4., Avdeenko Y2., Bogomolova T2., Ignatieva S2., Taraskina A.2, Burova S.A5., Vasylieva N.V.2
2024
40
n/a
-
v
Balogun O.J, Ajibola O.O.E., Oladele R.O., Fashanu T.A, Gangneux J.P., Denning D.W
2024
39
n/a
-
v
Su Chen, Ruoyu Li, Wei Chen, Zhe Wan, Wei Liu
2024
38
n/a
-
v
K.A. Marr,1,2 N. Permpalung,1 S. Rajack,1 K. Datta,1 D. Ostrander,1 J.F. Staab,1 K. Witwer,1 I. Baburina,2 D. Neitzey,2 P. X. Marques,2 R. Aerts,3 J. Maertens,3 D. Sheppard,4 J.R. Wingard,5 and S. X. Zhang,1
2024
37
n/a
-
v
Walshe. K, Dwyer. M and Doyle.S (IE)
2024
36
n/a
-
v
Jiří Houšť1, Radim Dobiáš2, Dominika Luptáková1, Andrea Palyzová1, Tomáš Pluháček1, Milan Navrátil3, David A. Stevens4, Rutuja H. Patil1, and Vladimír Havlíček1
2024
35
n/a
-
v
Mragnayani Pandey (IN), Immaculata Xess, Janya Sachdev, Neha Sharad, Sonakshi Gupta, Gagandeep Singh, Renu Kumari Yadav, Bhaskar Rana, Stephen Raj, M Nizam Ahmad, Neha Nityadarshini, Upendra Baitha, Manish Soneja, Shalimar, Bindu Prakash, Kapil Sikka, Purva Mathur, Viveka P Jyotsna, Rakesh Kumar, Naveet Wig, Ashutosh Biswas, Alok Thakar,
2024
34
n/a
-
v
Vladimir Havliecek1,2, R Dobias3,4, D Luptakova1, R Patil1,2, J Houst1,2, D Stevens5,6, M Petrik7, A Palyzova1, T Pluhacek1,2
2024
33
n/a
-
v
Sebastien Imbert (FR)
2024
32
n/a